 | • レポートコード：MRC2304L168 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、254ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査レポートでは、世界のRNA療法市場規模が2021年に1,567.35百万ドル、2022年に1,843.77百万ドルとなり、その後2027年までにCAGR 20.02％で成長して4,686.50百万ドルに達すると予測しています。当書は、RNA療法の世界市場を対象とした調査・分析結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、技術別分析（ラベリング、線形増幅、マイクロアレイ、RNAアンチセンス技術、RNA干渉技術）、用途別分析（癌、心臓血管、遺伝性疾患、感染症、腎臓病）、エンドユーザー別分析（学術研究、診断、創薬＆開発）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。また、当書には、Alnylam Pharmaceuticals, Inc.、Arbutus Biopharma Corporation、Arcturus Therapeutics Holdings Inc.、Arrowhead Pharmaceuticals, Inc.、Benitec Biopharma Limited、Biogen Inc.、BioNTech SE、Cartesian Therapeutics, Inc.、Cenix BioScience GmbHなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のRNA療法市場規模：技術別 - ラベリングの市場規模 - 線形増幅の市場規模 - マイクロアレイの市場規模 - RNAアンチセンス技術の市場規模 - RNA干渉技術の市場規模 ・世界のRNA療法市場規模：用途別 - 癌における市場規模 - 心臓血管における市場規模 - 遺伝性疾患における市場規模 - 感染症における市場規模 - 腎臓病における市場規模 ・世界のRNA療法市場規模：エンドユーザー別 - 学術研究における市場規模 - 診断における市場規模 - 創薬＆開発における市場規模 ・世界のRNA療法市場規模：地域別 - 南北アメリカのRNA療法市場規模 アメリカのRNA療法市場規模 カナダのRNA療法市場規模 ブラジルのRNA療法市場規模 ... - アジア太平洋のRNA療法市場規模 日本のRNA療法市場規模 中国のRNA療法市場規模 インドのRNA療法市場規模 韓国のRNA療法市場規模 台湾のRNA療法市場規模 ... - ヨーロッパ/中東/アフリカのRNA療法市場規模 イギリスのRNA療法市場規模 ドイツのRNA療法市場規模 フランスのRNA療法市場規模 ロシアのRNA療法市場規模 ... - その他地域のRNA療法市場規模 ・競争状況 ・企業情報 |
The Global RNA Therapy Market size was estimated at USD 1,567.35 million in 2021 and expected to reach USD 1,843.77 million in 2022, and is projected to grow at a CAGR 20.02% to reach USD 4,686.50 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the RNA Therapy to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Technology, the market was studied across Enabled Technologies and Enabling Technologies. The Enabled Technologies is further studied across Inhibition, Labeling, Linear amplification, Microarrays, Purification, and qRT-PCR. The Enabling Technologies is further studied across RNA Antisense Technologies and RNA Interference Technologies. The RNA Antisense Technologies is further studied across MicroRNA and Small interfering RNA.
Based on Application, the market was studied across Cancer, Cardiovascular, Genetic Disorders, Infectious Diseases, Kidney Diseases, Metabolic Disorders, Oncology, and Retinal Diseases.
Based on End User, the market was studied across Academic Research, Diagnostics, and Drug Discovery & Development.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Arkansas, California, Florida, Illinois, Kentucky, Minnesota, New Jersey, New Mexico, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for RNA Therapy market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the RNA Therapy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global RNA Therapy Market, including Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., Benitec Biopharma Limited, Biogen Inc., BioNTech SE, Cartesian Therapeutics, Inc., Cenix BioScience GmbH, Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., MiNA Therapeutics Limited, Moderna, Inc., NeuBase Therapeutics, Inc., Nordic Nanovector ASA, ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., Spark Therapeutics, Inc., and Triplet Therapeutics, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global RNA Therapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global RNA Therapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global RNA Therapy Market?
4. What is the competitive strategic window for opportunities in the Global RNA Therapy Market?
5. What are the technology trends and regulatory frameworks in the Global RNA Therapy Market?
6. What is the market share of the leading vendors in the Global RNA Therapy Market?
7. What modes and strategic moves are considered suitable for entering the Global RNA Therapy Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Target Specificity and Selectivity of Treatment and Diagnostics
5.1.1.2. Strategic Alliances & Funding Supported By Pharmaceutical Companies
5.1.1.3. Increased Potential of Virtual Drug Development Models
5.1.2. Restraints
5.1.2.1. Hurdles In Drug Delivery Commercialization
5.1.3. Opportunities
5.1.3.1. Increasing Usage in Cell-Based Cancer Immunotherapy
5.1.3.2. Significance of mRNA Medicine to Treat Deficiency and Genetic Disorders
5.1.3.3. Pipelined Clinical Trials of RNA-Based Therapeutics
5.1.4. Challenges
5.1.4.1. Risk Associated with Investment & Potential Outcomes
5.2. Cumulative Impact of COVID-19
6. RNA Therapy Market, by Technology
6.1. Introduction
6.2. Enabled Technologies
6.3.1. Inhibition
6.3.2. Labeling
6.3.3. Linear amplification
6.3.4. Microarrays
6.3.5. Purification
6.3.6. qRT-PCR
6.3. Enabling Technologies
6.4.1. RNA Antisense Technologies
6.4.2.1. MicroRNA
6.4.2.2. Small interfering RNA
6.4.2. RNA Interference Technologies
7. RNA Therapy Market, by Application
7.1. Introduction
7.2. Cancer
7.3. Cardiovascular
7.4. Genetic Disorders
7.5. Infectious Diseases
7.6. Kidney Diseases
7.7. Metabolic Disorders
7.8. Oncology
7.9. Retinal Diseases
8. RNA Therapy Market, by End User
8.1. Introduction
8.2. Academic Research
8.3. Diagnostics
8.4. Drug Discovery & Development
9. Americas RNA Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific RNA Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa RNA Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Alnylam Pharmaceuticals, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Arbutus Biopharma Corporation
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Arcturus Therapeutics Holdings Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Arrowhead Pharmaceuticals, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Benitec Biopharma Limited
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Biogen Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. BioNTech SE
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Cartesian Therapeutics, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Cenix BioScience GmbH
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Dicerna Pharmaceuticals, Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Ionis Pharmaceuticals, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. MiNA Therapeutics Limited
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Moderna, Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. NeuBase Therapeutics, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Nordic Nanovector ASA
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. ProQR Therapeutics N.V.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Sanofi S.A.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Silence Therapeutics PLC
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sirnaomics, Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Spark Therapeutics, Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Triplet Therapeutics, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing